Purpose: To describe the imaging findings of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with emphasis on early magnetic resonance imaging (MRI) findings.

Materials And Methods: The medical records and computed tomography, MRI, and bone scintigraphy images of 5 female and 1male patients (n = 6) between the ages of 49 and 79 years (mean age, 70 years) who had a diagnosis of BRONJ were retrospectively reviewed, and temporal changes in imaging features were noted.

Results: The earliest MRI finding was the loss of the normal T1 hyperintensity of fatty marrow in the mandible and maxilla. The MRI findings of more advanced BRONJ included bone destruction, soft tissue edema and enhancement, inferior alveolar nerve thickening, and pterygoid muscle swelling and enhancement. On computed tomography, sclerosis and subtle lucencies (widening) of the periodontal ligament and cortex and around the apices of the teeth in the early stage, and osteolytic bone lesions, cortical disruption, and frank bone fragmentation in the later stages were observed. Bone scintigraphy showed increased uptake early in the disease.

Conclusions: Osteonecrosis of the mandible and maxilla occurs as a complication of bisphosphonate treatment of bone metastasis and osteoporosis and typically manifests after a dental procedure. Magnetic resonance imaging and bone scintigraphy findings may precede clinical symptoms and mimic metastatic disease.

Download full-text PDF

Source
http://dx.doi.org/10.1097/RCT.0b013e31817e4986DOI Listing

Publication Analysis

Top Keywords

imaging findings
12
magnetic resonance
12
resonance imaging
12
bone scintigraphy
12
findings bisphosphonate-related
8
bisphosphonate-related osteonecrosis
8
osteonecrosis jaw
8
emphasis early
8
early magnetic
8
computed tomography
8

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

STEM Neurology & Neuropsychological0 Research Group Egypt (SNRGE), Port Said, Port Said, Egypt.

Background: Donepezil, an acetylcholinesterase inhibitor (AChEI), is an FDA-approved drug to treat these neurodegenerative diseases, e.g., Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI).

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Mayo Clinic, Rochester, MN, USA.

Recent breakthrough findings in clinical trials on amyloid-lowering therapies have led to the approval of these drugs for the treatment of amyloid- positive elderly individuals who show symptoms of mild cognitive impairment and mild dementia. The next frontier is the testing the efficacy of treatments for secondary prevention of AD dementia. Phase III trials in asymptomatic AD are already under way, raising a host of novel questions on the sequelae of trial participation such as the emotional and social repercussions of biomarker disclosure, understanding the risk of side effects and eventually weighing the risk-benefit ratio of amyloid-lowering treatment.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

University of California San Francisco (UCSF), San Francisco, CA, USA; Northern California Institute for Research & Education (NCIRE), San Francisco, CA, USA; San Francisco Veterans Administration Medical Center (SFVAMC), San Francisco, CA, CA, USA.

The Alzheimer's Disease Neuroimaging Initiative (ADNI) has made many important contributions to the development of Alzheimer's Disease (AD) disease modifying treatments and diagnostic biomarkers. Since its funding in 2004 by the National Institutes of Aging, the goal of ADNI has been the validation of biomarkers for AD treatment trials. ADNI has enrolled over 2,400 participants in the USA and Canada for longitudinal clinical, cognitive, and biomarker studies.

View Article and Find Full Text PDF

Background: Alzheimer's and related disorders (ADRD) represent a range of neurodegenerative conditions characterized by abnormal protein deposits in the brain. Despite advances, there is a need for enhanced diagnostic and treatment approaches that acknowledge the diversity of ADRD. This project introduces the Alzheimer's and Related Disorders Multicenter Archive (ARMA), a collaborative platform with an advanced Electronic Data Capture (EDC) system linked to Electronic Medical Records (EMR) designed to refine ADRD diagnosis and natural history understanding, thus informing precision medicine.

View Article and Find Full Text PDF

Background: Lyn kinase, a member of the Src family of tyrosine kinases, predominantly phosphorylates ITIM and ITAM motifs linked to immune receptors and adaptor proteins, and is emerging as a target for Alzheimer's disease (AD). The role of Lyn in TREM2-mediated microglial activation and phagocytosis, a critical pathway for clearing Aβ plaques, remains unclear and potent, selective, and brain penetrant Lyn inhibitors are unavailable. In this study, we report the characterization of Lyn kinase inhibitors from the literature as well as the establishment of an advanced virtual screening platform at the IUSM-Purdue-TREAT-AD center to identify new type II Lyn inhibitors suitable as molecular probes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!